PharmaSignal Take
This week’s events signal a continued focus on strategic M&A and licensing deals, particularly in genetic medicine and RNAi therapeutics. Lilly’s acquisitions and alliance with Innovent Biologics stress-test the assumption of platform scalability and integration readiness. Meanwhile, regulatory decisions are impacting market access and launch timing for a number of assets.
The PharmaSignal Weekly Brief – Global Pharma Roundup captures these themes, providing insights into the strategic decisions and execution risks faced by global pharma leaders.
M&A and Strategic Deals
- Lilly’s acquisition of Orna for $2.4B and partnership with Innovent Biologics for $9B underscore the company’s push into genetic medicine and the Chinese market, respectively. These deals highlight the strategic importance of platform scalability and geographic optionality. Read more →
- Madrigal’s partnership with a China biotech for RNAi drugs signals a growing interest in this therapeutic approach, with potential implications for future licensing and alliance management decisions. Read more →
Regulatory and Approvals
- FDA’s refusal to review Moderna’s mRNA Flu Vaccine and rejection of Regenxbio’s Gene Therapy for Hunter Syndrome underscore the regulatory hurdles facing novel therapies, impacting launch timing and competitive positioning. Read more →
- The FDA’s approval of Tenpoint’s Presbyopia Eye Drop and Cytokinetics’ Myqorzo for a heart condition signal potential lifecycle value shifts for these assets. Read more →
Pipeline and R&D Highlights
- Bayer’s Asundexian reducing stroke risk by 26% in trial and Alumis’ TYK2 psoriasis drug showing promise in trials highlight the potential for differentiation vs standard of care, but also underscore execution risks. Read more →
Market, Pricing and Policy Signals
- Express Scripts’ settlement with FTC over insulin pricing practices and Lilly’s strong 2025 sales projections for Zepbound and Mounjaro highlight the ongoing pressure on pricing corridors and the importance of accurate sales forecasting. Read more →
Stay updated — follow PharmaSignal on LinkedIn for deal-side analysis and weekly execution signals across global pharma.